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Backgroud: Diabetic microvascular changes are considered to be influenced by angiogenic factors. As a
compensatory mechanism, the expression of some angiogenic factors are elevated in ischemic myocardium. The
aim of this study was to investigate the changes of serum angiogenic factors, and the association among these
angiogenic factors, the severity of coronary artery stenosis and collateral vessels form in patients with diabetes and
unstable angina pectoris (UAP).
Methods: 42 patients with diabetes (diabetes group), 57 patients with UAP (UAP group), and 36 age-matched
healthy people (control group) were selected. Serum concentrations of angiogenic factors were measured using
cytokine array technology. The severity of coronary artery stenosis was scored using the angiographic Gensini score.
Coronary collateral vessels were scored according to Rentrop's classification.
Results: No significant differences in the serum concentrations of vascular endothelial growth factor (VEGF),
angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), angiogenin, angiostatin, basic fibroblast growth factor (bFGF) and
platelet-derived growth factor-BB (PDGF-BB) were detected between control group and diabetes group. But in
patients with diabetes complicated with UAP and in patients with UAP without diabetes, serum concentrations of
VEGF and Ang-2 were elevated (p < 0.01, p < 0.01). Only serum Ang-2 concentrations were significantly correlated
with Gensini score (r=0.585, p < 0.001), left ventricular end diastolic diameter (r=0.501, p < 0.001), left ventricular end
systolic diameter (r=0.563, p < 0.001) and left ventricular ejection fraction (r=−0.523, p < 0.001).
Conclusion: Serum concentrations of VEGF and Ang-2 were increased, and diabetes didn’t affect this increases in
patients with UAP. Serum Ang-2 concentrations were correlated with the severity of coronary artery stenosis.
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Diabetes mellitus is defined as a metabolic disorder, and
is an independent risk factor for a variety of cardiovascu-
lar diseases. The causes of accelerated cardiovascular
disease in diabetic patients are multifactorial, including
coronary artery disease and microvascular pathology. In
myocardium of diabetes, microvessels density is signifi-
cantly reduced, which is reflected by a significant de-
crease in blood flow [1,2]. In patients with diabetes, the
ability to respond to progressive coronary artery stenosis* Correspondence: Drzhiyuzeng@126.com
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reproduction in any medium, provided the orby growing coronary artery collaterals is also signifi-
cantly impaired [3,4]. These microvascular changes may
lead to reduced perfusion of myocardium and contribute
to adverse cardiovascular events [5,6].
Angiogenesis is a highly regulated process, requires
coordinated signaling events among a variety of angio-
genic factors. Diabetic microvascular complications are
considered to be influenced by angiogenic factors. Vascu-
lar endothelial growth factor (VEGF), angiopoietin-1
(Ang-1) and angiopoietin-2 (Ang-2) play crucial roles in
developmental blood vessel formation and regulation of
hypoxia-induced tissue angiogenesis [7-9]. In addition,
some other angiogenic factors and protein are also
involved in angiogenesis, such as angiogenin [10],. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and platelet-derived growth factor-BB (PDGF-BB) [13].
Previous studies have reported that the expression of
VEGF and Ang-1 were reduced, but angiostatin was
elevated in the diabetic myocardium [14,15]. However, the
changes of angiogenic factors expression in local tissues
are not always consistent with the changes of systemic
concentrations. Some studies reported that the serum
VEGF concentrations were no changed in diabetes alone
[16,17], but were elevated in diabetes with atherosclerosis
or diabetic retinopathy [18]. As a compensatory mechan-
ism, the expression of some angiogenic factors are
elevated in ischemic myocardium [19]. Some studies
showed serum concentrations and myocardial expression
of VEGF and Ang-2 were increased in acute coronary syn-
drome [20-22].
However, little studies reported the association
among circulating angiogenic factors, the severity of
coronary artery stenosis and collateral vessels form in
patients with diabetes and unstable angina pectoris
(UAP). Therefore, using protein array technology, we
examined the changes of serum angiogenic factors, in-
cluding VEGF, Ang-1, Ang-2, angiogenin, angiostatin,
bFGF and PDGF-BB, and the association among these
angiogenic factors, the severity of coronary artery sten-
osis and collateral vessels form in patients with diabetes
and UAP.
Methods
Patients recruitment and data collection
This study was approved by the Human Research Ethics
Committee of the first affiliated hospital of guangxi
medical university. Informed consent was obtained from
all patients. 42 patients with diabetes (diabetes group)
and 57 patients with UAP (UAP group) were selected for
study group, and 36 age-matched healthy people from
medical examination center were selected as control
group. The UAP group was divided into diabetes sub-
group (23 cases, UAP(DM) subgroup) and non-diabetes
subgroup (34 cases, UAP(non-DM) subgroup) according
to UAP with or without diabetes. UAP was defined as
the presence of typical angina at rest or on minimum ex-
ertion associated with acute and transient ST-T segment
ECG changes but with normal cardiac enzymes. Exclu-
sion criteria included symptomatic peripheral vascular
diseases, renal failure, liver diseases, malignancy, con-
nective tissue diseases, evidence of ongoing infection or
inflammation, significant valvular heart diseases and
atrial fibrillation.
For each patient, a data sheet was completed with the
patient’s name, identification number, age, gender, his-
tory of hypertension, cigarette smoking, family history of
coronary artery disease, and the results of laboratory
measurement. On a separate sheet, the patient’s Gensiniscore and collateral score were recorded by experienced
angiographers.Blood collection
Venous blood samples were taken from the patients
with diabetes and UAP on the next morning after ad-
mission, and were taken from control group at the time
of medical examination. The blood samples were placed
the dry tube without anticoagulant for half an hour at
room temperature, and then were centrifuged at 3000
rpm for 5 min. Serum supernatant was removed, and
stored at −80°C to be used in angiogenic factors level
assays. Serum concentrations of angiogenic factors were
measured by protein array.Measurement of angiogenic factors
Serum concentrations of angiogenic factors were mea-
sured using cytokine array technology (RayBiotech, Inc).
Briefly, 100ul sample diluent were added into each well
and incubated at room temperature for 30 min to block
slides. And then 100ul standard cytokines or samples were
added to each well, and incubated at room temperature
for 2 h. Arrays were washed 5 times. 80ul of the detection
antibody cocktail were added to each well, and incubated
at room temperature for 2 h. Arrays were washed 5 times.
80ul of Cy3 equivalent dye-conjugated streptavidin were
added to each well, and incubated at room temperature in
dark room for 1 h. Arrays were washed 5 times. Finally,
the signals were visualized through use of a laser scanner
equipped with a Cy3 wavelength. Data extraction were
done with the microarray analysis software.Measurement of coronary artery stenosis and collateral
vessels
Coronary artery stenosis and collateral vessels were
measured using coronary angiography. Standard angiog-
raphy, with 4 views of the left coronary artery and 2 views
of the right coronary artery, was used for interpretation.
The severity of coronary artery stenosis was scored using
the angiographic Gensini score [23]. Coronary collateral
vessels were scored according to Rentrop's classification
[24]. A grade of 0 was given for no visible collaterals, 1 for
small side branches filled, 2 for major side branches of the
main epicardial vessel filled, and 3 for main epicardial
vessel filled by collaterals. The angiograms were reviewed
and the severity of coronary artery stenosis and collateral
vessels were scored by an experienced angiographer, and
then reviewed by a separate angiographer who was
blinded to the initial reading. In cases of disagreement,
angiograms were reviewed by a third angiographer who
was blinded to the initial 2 readings and served as an
arbitrator.
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The numerical values were expressed as the mean±SD.
The data were analyzed using the SPSS12.0 statistical
software. Comparisons between groups were performed
by one-way ANOVA with S-N-K post hoc multiple
comparisons and independent-samples T test. The cor-
relations among study parameters were analyzed by
Pearson’s correlation test and multivariate linear re-
gression analysis. Statistical significance was defined as
p < 0.05.
Results
Patient characteristics and clinical data
The baseline clinical data were summarized in Table 1.
No significant differences existed between groups in
terms of age, gender, total cholesterol, HDL cholesterol,
LDL cholesterol, Triglycerides. As expected, patients
with diabetes had significantly higher levels of glycated
hemoglobin (HbA1c), fasting blood glucose (FBG) and
2-h postprandial blood glucose (PBG2h) compared with
nondiabetic patients (p < 0.01). In addition, compared
with UAP(DM) subgroup, serum levels of HbA1c, FBG
and PBG2h were significantly increased in diabetes
group.Table 1 Baseline clinical characteristics of all subjects
Control Diabetes
(n=36) (n=42)
Age (years) 59.2 ± 7.5 55.92 ± 14.72
Male, n (%) 21 (58) 23 (57)
Smoking, n (%) 11 (30) 13 (31)
Hypertension n (%) 0 (0) 17 (40)
Total cholesterol (mmol/l) 4.37 ± 1.23 4.69 ± 1.02
HDL cholesterol (mmol/l) 1.25 ± 0.46 1.30 ± 0.40
LDL cholesterol (mmol/l) 2.83 ± 0.96 3.07 ± 0.823
Triglycerides (mmol/l) 1.65 ± 1.32 1.95 ± 1.50
HbA1c (%) - 9.09 ± 3.01
FBG (mmol/L) 5.36 ± 1.82 11.84 ± 6.67
PBG2h (mmol/L) - 14.55 ± 7.75
Diabetes duration (year) - 5.61 ± 2.95
Medications, n (%)
Insulin - 6 (14)
Antidiabetics - 19 (45)
Statin - 15 (35)
Aspirin - 17 (40)
Clopidogrel - 0 (0)
ACE inhibitor - 11 (26)
Beta-receptors blocker - 3 (7)
Nitroglycerin - 0 (0)In diabetes group, there were 16 patients with albu-
minuria, 5 patients with peripheral neuropathy. In UAP
(DM) subgroup, there were 9 patients with albuminuria,
3 patients with peripheral neuropathy. There were not
clinical evidence of other complications.
Changes of serum angiogenic factor concentrations in
diabetic patients
Serum concentrations of VEGF, Ang-1, Ang-2, Angiogenin,
Angiostatin, bFGF and PDGF-BB were measured using
cytokine array technology. The results showed there were
no significant differences in the serum concentrations of all
7 angiogenic factors between control group and diabetes
group. We also examined the serum concentrations of
angiogenic factors in diabetic patients with UAP. The
results showed the serum concentrations of VEGF and
Ang-2 were significantly increased, and the serum
concentrations of the other angiogenic factors were not
changed in diabetic patients with UAP compared with con-
trol group (Table 2).
Changes of serum angiogenic factor concentrations in
patients with UAP
The results showed the serum concentrations of VEGF and
Ang-2 were significantly increased in UAP group comparedUAP(DM) UAP(non-DM)
P Value
(n=23) (n=34)
59.3 ± 8.65 60.52 ± 9.86 NS
14 (61) 22 (64) NS
8 (34) 13 (38) NS
14 (60) 18 (53) < 0.01
4.40 ± 1.12 4.62 ± 1.35 NS
1.32 ± 0.42 1.53 ± 0.54 NS
2.53 ± 1.44 2.75 ± 1.05 NS
1.89 ± 1.76 1.79 ± 1.68 NS
8.33 ± 3.52 5.62 ± 0.86 < 0.01
8.3 ± 4.1 6.13 ± 1.34 < 0.01
11.23 ± 6.31 7.32 ± 1.51 < 0.01
6.48 ± 3.62 - NS
3 (13) - NS
13 (56) - NS
19 (83) 26 (76) < 0.01
21 (91) 29 (85) < 0.01
5 (22) 6 (18) < 0.01
12 (52) 16 (47) < 0.01
7 (30) 13 (38) < 0.01
8 (35) 13 (38) < 0.01
Table 2 Serum concentrations of angiogenic factors in different groups (pg/ml)
Control Diabetes UAP(DM) P value
(n=36) (n=42) (n=23) (ANOVA)
Angiogenin 4403.05 ± 850.27 4432.91 ± 1009.52 4375.56 ± 911.94 0.879
Ang-1 38647.4 ± 17964.15 39672.61 ± 14701.38 45267.17 ± 17279.20 0.205
Ang-2 2444.50 ± 1152.21 2864.76 ± 1436.20 3532.10 ± 1813.72 < 0.01
Angiostatin 7282.67 ± 2678.44 6602.22 ± 2357.75 8145.66 ± 3600.28 0.163
bFGF 890.05 ± 518.09 932.81 ± 384.60 767.36 ± 546.01 0.252
PDGF-BB 10986.56 ± 5571.85 10264.32 ± 5427.67 10737.34 ± 2851.41 0.836
VEGF 171.92 ± 106.63 239.24 ± 115.80 286.90 ± 217.01 < 0.01
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nificant differences in the serum concentrations of
angiogenin, Ang-1, angiostatin, bFGF and PDGF-BB were
detected between control group and UAP group (Table 3).
In order to observe the influence of diabetes on the
serum concentrations of angiogenic factors in patients
with UAP, we compared the serum concentrations of
angiogenic factors between UAP patients with and with-
out diabetes. The results showed there were no signifi-
cant differences in the serum concentrations of all 7
angiogenic factors between UAP(DM) subgroup and
UAP(non-DM) subgroup (Table 4).Correlation of angiogenic factors with other parameters
All 57 patients with UAP were undergone coronary angiog-
raphy. The Table 5 showed the echocardiographic
parameters, Gensini score, collateral score and serum NT-
proBNP concentrations. By Pearson’s correlation and multi-
variate linear regression analysis in UAP group, serum
VEGF and Ang-2 concentrations were unrelated to total
cholesterol, HDL cholesterol, LDL cholesterol, triglycerides,
HbA1c, FBG, PBG2h, serum NT-proBNP concentrations
and collaterals score. Serum Ang-2 concentrations, but not
VEGF concentrations, were significantly correlated withTable 3 Serum angiogenic factors concentrations in
control and UAP group (pg/ml)
Control UAP P value
(n=36) (n=57) (T test)
Angiogenin 4403.05 ± 850.27 4091.73 ± 784.89 0.105
Ang-1 38647.4 ± 17964.15 41182.45 ± 13633.35 0.456
Ang-2 2444.50 ± 1152.21 3679.91 ± 1880.94 < 0.01
Angiostatin 7282.67 ± 2678.44 7661.21 ± 3283.94 0.593
bFGF 890.05 ± 518.09 757.32 ± 544.35 0.191
PDGF-BB 10986.56 ± 5571.85 10880.50 ± 2307.80 0.941
VEGF 171.92 ± 106.63 319.35 ± 242.59 < 0.01Gensini score, left ventricular end diastolic diameter
(LVEDD), left ventricular end systolic diameter (LVESD)
and left ventricular ejection fraction (LVEF) (Figure 1,
Figure 2).Discussion
This is the first study simultaneously investigating circu-
lating levels of 7 angiogenic factors in patients with dia-
betes and UAP. This study found that: (1) There were
no significant differences in the serum concentrations of
all 7 angiogenic factors between control group and dia-
betes group; (2) Serum concentrations of VEGF and
Ang-2 were elevated in UAP patients with or without
diabetes, and diabetes didn’t affect the elevation of
serum VEGF and Ang-2 concentrations; (3) Only serum
Ang-2 concentrations were significantly correlated with
Gensini score, LVEDD, LVESD and LVEF.Changes of the serum concentrations of angiogenic
factors in diabetes alone
Many studies have demonstrated the alterations of various
angiogenic factors in local tissues in the setting of diabe-
tes. It is established that VEGF expression in diabetic myo-
cardium is decreased [2,14,25]. Huang et al. reported thatTable 4 Serum angiogenic factors concentrations in UAP
with or without diabetes subgroup (pg/ml)
UAP(DM) UAP(non-DM) P value
(n=23) (n=34) (T test)
Angiogenin 4375.56 ± 911.94 3914.33 ± 663.69 0.077
Ang-1 45267.17 ± 17279.20 38629.50 ± 10609 0.072
Ang-2 3532.10 ± 1813.72 3773.30 ± 1812.38 0.633
Angiostatin 8145.66 ± 3600.28 7358.43 ± 3153.14 0.357
bFGF 767.36 ± 546.01 748.53 ± 558.83 0.891
PDGF-BB 10737.34 ± 2851.41 10969.97 ± 1994.01 0.714
VEGF 286.90 ± 217.01 339.63 ± 262.08 0.391
Table 5 Parameters of cardiac function and coronary
artery in UAP group
UAP(DM) UAP(non-DM) P Value
(n=23) (n=34) (T test)
LVEF (%) 56.50 ± 7.95 59.09 ± 9.96 NS
LVEDD (mm) 54.76 ± 7.34 52.56 ± 9.72 NS
LVESD (mm) 38.24 ± 6.72 36.22 ± 9.65 NS
Gensini score 41.04 ± 24.52 38.59 ± 22.62 NS
Collateral score 0.78 ± 0.99 0.91 ± 1.03 NS
NT-proBNP (pg/ml) 1743.87 ± 2521.32 1513.67 ± 2102.53 NS
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to high glucose stimulation was significant decreased [26].
But VEGF expression in different tissues is different in dia-
betes. For example, VEGF expression in the retina and renal
glomeruli are increased in diabetes [14]. Circulating VEGFFigure 1 Correlations between serum Ang-2 concentrations and Gens
(Pearson’s r=0.585, p < 0.001); (B): Ang-2 and LVEDD (Pearson’s r=0.501, p <
and LVEF (Pearson’s r=−0.523, p < 0.001).may not entirely reflect expression within the myocardium
and endothelial cell, it also may derive from other tissues
and cells. Some studies reported the serum VEGF con-
centrations were not changed in diabetes alone [16,17]. So
this study supports the results of previous studies.
Some studies have reported the expression of Ang-1
was reduced, but angiostatin was elevated in the diabetic
myocardium [15,27]. However, the changes of angiogenic
factors expression in local tissue are not always consist-
ent with the changes of serum concentrations. Lim et al.
reported plasma Ang-1 was no changed in diabetes
[28,29]. Siebert et al. reported the serum angiogenin
levels were decreased in diabetic patients [30,31]. But
another study reported serum angiogenin concentrations
were increased in diabetic children [32]. We detected no
significant differences in serum concentrations of all
7 angiogenic factors between control group and diabetes
group. The changes of angiogenic factors expression inini score, LVEDD, LVESD and LVEF. (A): Ang-2 and Gensini score
0.001); (C): Ang-2 and LVESD (Pearson’s r=0.563, p < 0.001); (D): Ang-2
Figure 2 Correlations between serum VEGF concentrations and Gensini score, LVEDD, LVESD and LVEF. (A): VEGF and Gensini score
(Pearson’s r=0.173, p=0.199); (B): VEGF and LVEDD (Pearson’s r=0.179, p=0.184); (C): VEGF and LVESD (Pearson’s r=0.187, p=0.164); (D): VEGF and
LVEF (Pearson’s r=−0.169, p=0.209).
Gui et al. Cardiovascular Diabetology 2013, 12:34 Page 6 of 8
http://www.cardiab.com/content/12/1/34different tissues are different in diabetes, which may
cause no differences in serum concertrations.
Changes of the serum concentrations of angiogenic
factors in UAP
Some angiogenic factors can be induced by myocardial
ischemia. Matsunaqa et al. reported myocardial expres-
sion of VEGF and Ang-2 were increased in coronary
heart diseases [20]. Previous studies showed serum con-
centrations of VEGF and Ang-2 were significantly in-
creased, and Ang-1 were not changed in patients with
acute coronary syndrome [21,22]. This study also showed
serum concentrations of VEGF and Ang-2 were increased
in UAP patients with or without diabetes, which were
consistent with previous studies. Antonio et al. reported
that plasma angiogenin levels were significantly increased
in acute coronary syndromes, but not changed in stable
coronary artery disease [33]. The acute coronary syn-dromes in Antonio’s study included 49.7% raised troponin
T, which was more severe than that in our study.
Diabetes is associated with reduced expression of myo-
cardial angiogenic factors during ischemia [34]. So this
study examined whether the serum concentrations of-
angiogenic factors during unstable angina were influ-
enced by diabetes. This study showed there were no
significant differences in the serum concentrations of all
7 angiogenic factors between UAP patients with and
without diabetes. The expression of angiogenic factors in
local tissues, rather than systemic concentrations of
angiogenic factors may be influenced by diabetes.
Ang-2 but not VEGF is correlated with the coronary artery
stenosis
It is well established that Ang-2 modulates endothelial
cell biology and destabilizes blood vessels to facilitate
angiogenesis [35]. Ang-2 promotes also VEGF induced
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expressed only at sites of vascular remodeling [38], so
circulating levels of Ang-2 may acutely reflect the vascu-
lar regeneration and repair. However, VEGF is expressed
in many cells, such as endothelial cells, macrophages,
smooth muscle cells and cardiocytes. In addition, there
is a tremendous interindividual variability in the degree
of the hypoxic regulation of VEGF [39]. These factors
may be the causes that Ang-2 but not VEGF is
correlated with the coronary artery stenosis.
Chong et al. reported plasma Ang-2 and VEGF levels
were increased in chronic heart failure, and Ang-2
concentrations were correlated with LVEF [40]. But the
etiology of heart failure were not described in Chong’s
study. Our study showed LVEDD, LVESD and LVEF
were significantly correlated with Gensini score. So the
interpretation may be that the severity of coronary artery
stenosis is the key determinate factor for Ang-2, and the
changes in heart dysfunction are merely a reflection of
the consequences of stenosis severity. Further research
will be needed about the association of Ang-2 and heart
failure independent of underlying coronary artery
stenosis.
Development of collateral vessels is triggered by the
pressure gradient between the coronary arteries bed
caused by an obstruction. This study found that patients
with well developed collaterals had more severe coron-
ary artery stenosis. Coronary artery stenosis severity
other than serum angiogenic factors levels may mainly
determine the degree of coronary collateral formation.
Some studies have reported some angiogenic protein in
pericardial fluid were correlated with coronary collateral
growth [41,42]. However, Sherman et al. reported that
the degree of coronary collateral formation was not de-
termined by differences in systemic levels of angiogenic
factors [43]. The expression of angiogenic factors in local
tissues, rather than systemic levels of angiogenic factors
may affect coronary collateral formation.
Conclusions
This study showed serum concentrations of VEGF and
Ang-2 were increased, and diabetes didn’t affect this
increases in patients with UAP. Serum Ang-2 concen-
trations were correlated with the severity of coronary
artery stenosis.
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